Program
FXS4640
A development code. Also written as “[¹⁴C]FXS4640”.
In Fosun Pharma's pipeline, PLK1
. Its studies are led by Fosun Pharma.
Furthest: phase 1, since Sep 23, 20261 company-led study, 1 open or runningNext primary completion: Nov 16, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 11 open or running | phase 1since Sep 23, 2026 | Sep 23, 2026 | Nov 16, 2026phase 1 · NCT07872579 |
- Named in Fosun Pharma’s own pipeline as
FXS4640 (PLK1)
, phase 2, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 23, 2026First study: phase 1 study in Healthy SubjectsFirst studyNCT07872579 · 6 planned · China
Ahead
- Nov 16, 2026Primary completion: phase 1 study in Healthy SubjectsNCT07872579
TargetBeta
“PLK1”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07872579Healthy Subjects · China | 1 | Not yet recruiting | Nov 16, 2026 | 6 |
How it is read
Names in the registry
- “[¹⁴C]FXS4640”, 1 entry
Codes read as this program: FXS4640.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.